ClinicalTrials.gg
RecruitingNCT06291155Updated Jun 11, 2026

Mechanism of SGLT2 Inhibition in the Kidney

A Phase 4 interventional study of SGLT2 inhibitor in Type 2 Diabetes and Diabetic Kidney Disease, sponsored by University of Michigan. Recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-11.

Sponsored by University of Michigan · Phase 4, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 507 studies testing SGLT2 inhibitors in Diabetes Mellitus, Type 2 — 47 open to participants now, 57 under way, 11 of them phase 3. A drug class: SGLT2 inhibitors · Diabetes Mellitus, Type 2.

Planned enrollment
452nd of 507
20 · median 90
Started
2024
with 15 others
Phase 4
158 of 507
25 open now
Primary completion
2027-12
later than 44 of 56 live
Registered
454th of 507
by date

Among the 507 studies testing SGLT2 inhibitors in Diabetes Mellitus, Type 2, this one is the 452nd largest by planned enrollment, is one of 16 that started in 2024, is one of 158 in phase 4, reaches primary completion later than 44 of the 56 other live ones, and was the 454th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

47 of the 507 studies testing SGLT2 inhibitors in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

41 more — sign in →

By country, each count listing its studies:

All 47 open studies →

About SGLT2 inhibitors

A class of medicines: which ones, and the studies of each, are on its page →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 507 studies testing SGLT2 inhibitors in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The goal of this open-label, non-randomized clinical trial is to determine what effects, if any, an FDA-approved drug class known as SGLT2 inhibitors (Canagliflozin or INVOKANA) has any protective effects on kidney function in Type 2 diabetes. We are looking for participants 18-80 years of age, who have had a clinical diagnosis of Type 2 diabetes for ≥ 3 years.

Participants will be asked to sign a consent and complete a screening visit prior to study entry including the following procedures for this study:

Consent and Screening:

  • Laboratory tests to determine baseline health
  • Ultrasound to measure kidney size and ensure presence of 2 functioning kidneys

Month 0:

  • Study entry kidney MRI (day 0)
  • Study entry kidney biopsy (within 30 days of MRI)
  • Study entry visit for dispensing 100 mg/daily Canagliflozin medication 3 month supply

Month 3:

  • Study visit to dispense remaining 3 months of 100 mg/daily Canagliflozin medication
  • Review of systems

Month 6:

  • Follow-up kidney MRI
  • Follow-up kidney biopsy

Study participants will also be requested to provide blood and urine samples for biobanking purposes. They will also be provided the opportunity to provide a stool sample at two time points, as well as the option to participate in a related study collecting samples to create induced Pluripotent Stem Cells (iPSCs).

Participants will be compensated for their time and loss of work time, additionally, a nominal additional compensation for optional stool and iPSC samples.

Read the detailed description

The purpose of this protocol is to examine the effects of the sodium-glucose cotransporter 2 (SGLT2) inhibitor canagliflozin on intrarenal transcripts of energy metabolism in adults with type 2 diabetes and early diabetic kidney disease (DKD) via an open-label non-randomized mechanistic trial. This trial will enroll 40 participants who will receive 100 mg of canagliflozin daily for six (6) months in addition to standard of care. The primary objective of this study is to determine whether canagliflozin affects intrarenal transcripts of energy metabolism in adults with type 2 diabetes and early DKD.

The primary outcomes measure will be change in transcripts as assessed by single-cell RNA sequencing of kidney biopsy specimens obtained at study entry and after 6 months of study drug. Secondary outcomes include assessing the effects of canagliflozin on structural progression of DKD assessed by morphometric examination of kidney tissue specimens from the paired research biopsies. Additional secondary outcomes include measures of glomerular filtration rate (GFR) and renal plasma flow (RPF) as well as multiparametric kidney MRI. Magnetic resonance imaging of the kidneys will be performed prior to each biopsy to correlate the molecular and structural damage seen at kidney biopsy with the level of perfusion, oxygen availability and fibrosis detected by imaging. Imaging of the kidneys will be done as near to the time of each kidney biopsy as possible. Participants will be followed annually after completion of the mechanistic clinical trial until death or development of end-stage kidney disease.

Participants will be followed for potential adverse events for an additional two months post six-month biopsy.

03

Conditions studied

  • Type 2 Diabetes
  • Diabetic Kidney Disease

Keywords

  • Kidney biopsy
  • Kidney MRI
  • SGLT2 inhibitor
  • SGLT2i
  • FDA-approved
  • Renal biopsy
  • Renal MRI
  • Type 2 diabetes
  • Canagliflozin
  • INVOKANA
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18-80 years.

    • The lower age limit was set so renal function test results would not reflect changes associated with growth.
  • Diagnosis of type 2 diabetes for ≥ 3 years.
  • Estimated >45 and \< 90 ml/min/1.73m2 as determined from the CKD-EPI equation using serum creatinine (Levey et al., 2009)
  • A screening urinary albumin-to-creatinine ratio \<3000 mg/g.
  • Willingness to participate after receiving a thorough explanation of the study.
  • Participants receiving a RAAS inhibitor must have been receiving the drug at maximum tolerable dose for at least 3 months prior to the study baseline examination.
  • Participants receiving a GLP-1 receptor agonist must have been receiving the drug for at least 3 months prior to the study baseline examination.
  • Participants must meet the current clinical guidelines for prescribing SGLT2 inhibitors, to maintain FDA-approved standards

Exclusion criteria

Exclusion Criteria:

  • disorders of the liver [cirrhosis, portal hypertension, hepatitis, increased (≥1.5 mg/dl), active or uncontrolled cardiovascular disease, symptomatic peripheral vascular disease, (i.e. intermittent claudication), pulmonary diseases (including uncontrolled asthma and restrictive or obstructive lung disease requiring therapy), renal-urinary disorders (calculi, urinary tract obstruction, glomerulonephritis, chronic infection), gastrointestinal disorders (nausea, vomiting, diarrhea or anorexia sufficient to cause weight loss or wasting), or hematocrit levels ≤30 percent in women or ≤35 percent in men.
  • Prior and ongoing treatment with SGLT2 inhibitors
  • Renovascular or malignant hypertension; uncontrolled hypertension (systolic blood pressure ≥150 or diastolic ≥90 mm Hg)
  • Hematuria of unknown etiology.

    • Prior to entry into the study, any participant with hematuria should be evaluated, the etiology established and documented, and treatment rendered as appropriate.
  • Chronic debilitating disorders with or without treatment (e.g., systemic lupus erythematosus [SLE], cancer, amyloidosis, and chronic infection) that would interfere with the assessment of kidney function or that might reduce the chances of survival for a sufficient length of time to evaluate the efficacy of treatment.
  • Currently receiving a drug regimen that includes , , or new drugs not associated with this trial.
  • Pregnancy.

    • SGLT2 inhibitors are not recommended during the second or third trimester of pregnancy. Moreover, we do not wish to expose pregnant women to conscious sedation that is used during the kidney .. Women of must have a negative pregnancy test prior to entry and every 2 months during the study and agree to using an effective form of throughout the study, such as the oral contraceptive pill or an intrauterine device. Women who are planning a pregnancy in the next three years will be excluded.
  • Known to canagliflozin or iodine.
  • Bleeding disorders or requirements for anticoagulation or inhibitors which cannot be safely interrupted since kidney biopsies cannot be performed safely in these individuals.
  • Massive obesity with ≥45 kg/m².

    • Kidney biopsies are more technically difficult with massive obesity.
  • Allergy to iodine-containing contrast material or shellfish.
  • Non-diabetic kidney disease - based on clinical history or kidney biopsy examination.
  • History of osteoporotic fracture.
  • History of lower-limb amputation irrespective of etiology
  • Conditions likely to interfere with or compliance with the protocol.
  • Known solitary kidney
  • Size of one or both kidneys on ultrasound \< 9 cm (small kidney size is concerning for renal atrophy due to underlying kidney disease) or > 2 cm discrepancy between left and right kidney sizes based on largest longitudinal diameter
  • Current use of UGT enzyme inducters, lithium, and digoxin
  • Blood urea nitrogen (BUN) > 80 gm/dL
  • > 1.4 (a)
  • PTT > 35 seconds (a)
  • Platelet count \< 100,000 uL (a)
  • (Hgb) \< 10 mg/dL (a)
  • Hydronephrosis or other important renal ultrasound findings such as significant stone disease

    1. Inclusion possible after this has been obtained within range
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 4
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Other
    SGLT2i Arm

    Drug: SGLT2 inhibitor

Interventions

  • DrugSGLT2 inhibitorsStudies of SGLT2 inhibitorsSGLT2 inhibitors pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    All participants will be receive 100 mg/daily doses of Canagliflozin (INVOKANA) for 6 months. Canagliflozin is a Sodium-glucose cotransporter 2 (SGLT2) inhibitor

    Also known as: Canagliflozin, Invokana

06

What researchers measure

Primary outcomes

  1. Glomerular basement membrane (GBM) width and mesangial expansion

    Measured by morphometric examination of kidney tissue

    Time frame: Baseline and 6 months

Secondary outcomes

  1. Kidney Transcript Changes

    Molecular changes measured by change in transcripts as assessed by single-cell RNA sequencing of kidney biopsy specimens

    Time frame: 6 month follow-up

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Dec 2027, 47 months after the start.

Of 320 non-industry phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 49. This study's planned 47 months is above that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2024
First posted
Mar 4, 2024
StartActual
Jan 1, 2024
Primary completionEst.
Dec 31, 2027
CompletionEst.
Feb 28, 2028
Last update
Jun 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06291155
Responsible party
Markus Bitzer (Professor of Internal Medicine, University of Michigan) — Principal investigator
First posted
Mar 4, 2024
Start date
Jan 1, 2024
Primary completion
Dec 31, 2027 (estimated)
Completion
Feb 28, 2028 (estimated)
Last update
Jun 11, 2026

Study contacts

Chrysta C Lienczewski, BS
Contact
boridley@umich.edu
734-615-5021
Markus Bitzer, MD
principal investigator · Professor of Internal Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SGLT2 inhibitors

Start the discussion